Cardiology/Vascular Diseases | Phase I Developments

SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China

Lead Product(s): JK07

Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Carlyle

Deal Size: $260.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition September 01, 2020

Details:

Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.

Arrowhead Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at the ESC Congress 2020

Lead Product(s): ARO-APOC3

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-APOC3

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2020

Details:

Presentation to showcase Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 being developed as a treatment for mixed dyslipidemias.

Miragen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

miRagen Together with Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data

Lead Product(s): MRG-110

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MRG-110

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2020

Details:

Data demonstrate that a single systemic dose of MRG-110 reduced detectable miR-92a levels in the peripheral blood of humans and led to the regulation of several well established miR-92a target genes.

Staten Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

The Netherlands

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Staten Biotechnology, In Collaboration with Novo Nordisk, Starts Dosing of Anti-ApoC3 Antibody SST-5058 in First-in-Human Trial

Lead Product(s): SST-5058

Therapeutic Area: Cardiology/Vascular Diseases Product Name: SST-5058

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Novo Nordisk

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk.

Shionogi Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Shionogi Signs New Contract with StemRIM Toward Investigator-initiated Clinical Study Implementation of S-005151

Lead Product(s): Redasemtide

Therapeutic Area: Cardiology/Vascular Diseases Product Name: S-005151

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: StemRIM

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 30, 2020

Details:

The companies have entered a licensing agreement for S-005151 [Generic name: Redasemtide] to conduct investigator-initiated clinical studies targeting new indications in the future.

Gesynta Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

Lead Product(s): BI1029539

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

The clinical study was aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI to healthy subjects after single and multiple ascending dosages.

Silence Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics

Lead Product(s): Small interfering RNA

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: $2,080.0 million Upfront Cash: $60.0 million

Deal Type: Collaboration March 26, 2020

Details:

Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.

Heartseed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

Lead Product(s): Allogeneic iPSC-derived cardiomyocytes

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Itochu Chemical Frontier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 10, 2020

Details:

Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.

Grindeks AS

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

LATVIA Latvia

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Grindeks has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB

Lead Product(s): Methyl-GBB

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

Preclinical studies have demonstrated the efficacy of the new molecule in reducing heart infarct size as a result of mitochondrial protection and attenuation of atherosclerosis progression.

Cytokinetics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Cytokinetics Announces Preclinical Data For AMG 594 Presented At The Keystone Symposium On Heart Failure.

Lead Product(s): AMG 594

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

In vitro studies demonstrate cardiac troponin activator selectively activates cardiac muscle fibers with little effect on slow skeletal muscle or fast skeletal muscle.

Find

Find Drugs for Cardiology/Vascular Diseases in Phase I Clinical Development

Phase I

Product Type

Companies

SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.

Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China

Arrowhead Pharmaceuticals

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at the ESC Congress 2020

Miragen Therapeutics

miRagen Together with Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data

Staten Biotechnology

Staten Biotechnology, In Collaboration with Novo Nordisk, Starts Dosing of Anti-ApoC3 Antibody SST-5058 in First-in-Human Trial

Shionogi Inc

Shionogi Signs New Contract with StemRIM Toward Investigator-initiated Clinical Study Implementation of S-005151

Gesynta Pharma

Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

Silence Therapeutics

Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics

Heartseed

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

Grindeks AS

Grindeks has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB

Cytokinetics

Cytokinetics Announces Preclinical Data For AMG 594 Presented At The Keystone Symposium On Heart Failure.